Share this post on:

product name Q-VD-OPh


Description: Q-VD-OPh is a potent pan-caspase inhibitor with IC50 ranging from 25 to 400 nM for caspases 1, 3, 8, and 9, showing inhibitory effects on terminal caspase activation, substrate cleavage, and DNA ladder formation associated with apoptosis. Q-VD-OPh was equally effective at inhibiting the three major apoptotic pathways, was functional in different cell types and species (human, mouse, and rat) and prevented terminal caspase activation, substrate cleavage, and DNA ladder formation associated with apoptosis. The effectiveness of Q-VD-OPh as an apoptotic inhibitor is evidenced by the complete suppression of an apoptotic inducer capable of inducing substantial cell death in less than 4 hours.

References:  Apoptosis. 2003 Aug;8(4):345-52.



Molecular Weight (MW)

513.49
Formula

C26H25F2N3O6
CAS No.

1135695-98-5
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO: 100 mg/mL (194.74 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: 100 mg/mL (194.74 mM)
Solubility (In vivo)

 
Chemical Name

(3S)-5-(2,6-difluorophenoxy)-3-[[(2S)-3-methyl-2-(quinoline-2-carbonylamino)butanoyl]amino]-4-oxopentanoic acid

other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19404957

Q-VD-OPh (5-100 μM) potently inhibits Actinomycin D-induced DNA laddering and subsequent apoptosis with minimal toxicity in WEHI 231 cells. Q-VD-OPh prevents caspase mediated cleavage of PARP and activation of the major initiator and effector caspases. Q-VD-OPh protects cardiac myocytes from virus-induced apoptosis in vitro
In Vivo Q-VD-OPh inhibited caspase-7 activation and limited the pathological changes of tau and caspase cleavage in chronic treatment of Alzheimer disease.
Animal model TgCRND8 mice in 3 months-old
Formulation & Dosage Intraperitoneally Injected with 10 mg/kg QVD-OPh at 3 times a week for 3 months
References J Cell Biochem. 2011 Nov;112(11):3334-42; Int J Clin Exp Med. 2009 Nov 5;2(4):300-8.

LXR-623